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Background: Literature data suggest with some criticism that full-fledged cardiovas-
cular (CV) events (acute or chronic) are likely predicted by blood components, which are 
reported to be associated with the presence/severity of non-alcoholic fatty liver disease 
(NAFLD). This study was aimed at determining which marker(s) derived from blood 
count, such as white blood cells, neutrophils, neutrophil/lymphocyte ratio, platelet 
count, hemoglobin, mean corpuscular volume, hematocrit values were associated with 
ear or subclinical atherosclerosis, in obese patients of various classes suffering from 
NAFLD.
Methods: One hundred consecutive obese patients presenting NAFLD at ultrasound, 
with low prevalence of co-morbidities and no history or instrumental features of CV 
diseases, underwent carotid intima-media thickness (IMT) assessment by Doppler ultra-
sonography. All of them were studied taking into account anthropometric parameters, 
the metabolic profile, and inflammatory markers.
results: White blood cells and neutrophil count showed no statistical association 
with IMT, which was predicted by the amount of visceral adiposity, as appreciated by 
ultrasonography. After adjusting for visceral adiposity and smoking status, only age 
and hematocrit contextually predicted early atherosclerosis, evaluated as IMT. Visceral 
adiposity was a confounding factor in foreseeing IMT.
conclusion: Hematocrit values along with the patient’s age suggest an initial atheroscle-
rosis, evaluated as IMT, and if this finding is confirmed in larger cohorts, could be added 
to other canonical CV risk factors. Inferences can be enhanced by future prospective 
studies that aim to identify the relationships between incident cardio-metabolic cases 
and this hematologic parameter.
Keywords: hematocrit, carotid intima-media thickness, obesity-related non-alcoholic fatty liver disease, Us, 
cV risk
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inTrODUcTiOn
Literature data show that both full-fledged cardiovascular (CV) 
events (acute or chronic) and mortality derived from CV disease 
are likely predicted by blood components, but there are also dis-
senting studies.
In fact, while high count of white blood cells is an independ-
ent predictor of coronary artery disease risk in patients of both 
genders (1), also after adjusting for the classical risk factors (2), 
further research has failed to discern any association between 
hematological indices and coronary calcification (3). Markers 
including coronary artery calcification, carotid intima-media 
thickness (IMT), and ankle-brachial index can be used to assess 
CV risk, even in patients with no symptoms of heart disease. 
Indeed, the coronary artery disease risk associated with high 
white blood cells count was comparable to those of other inflam-
matory markers (4). Interestingly, higher levels of white blood 
cells are independently related to the presence of non-alcoholic 
fatty liver disease (NAFLD) (5), a condition reckoned as a CV 
risk per se.
Not only with total count of white blood cells was an asso-
ciation of the long-term carotid artery disease-related mortal-
ity found but also with an its subtype, i.e., neutrophil count 
(6, 7). In keeping with the subtypes of white blood cells, atten-
tion has been directed to predict coronary artery disease using 
the neutrophil-to-lymphocyte ratio (8, 9). Furthermore, the 
neutrophil-to-lymphocyte ratio is higher in patients with the 
most severe form of NAFLD (10, 11), although this finding has 
not been confirmed (12). Literature offers contrasting data about 
hemoglobin levels. In fact, lower levels are independent predictor 
of late mortality in patients undergoing coronary artery bypass 
grafting (13) while higher levels seem to predict the histological 
severity of NAFLD (14).
A blood constituent that has captured the interest of many 
researchers is hematocrit, which is an independent risk factor 
for CV mortality (15). But, also in this context, there is some 
disagreement. Whereas patients with chronic cerebral infarc-
tions had hematocrit values significantly related to the carotid 
IMT (16), a meta-analysis comparing hematocrit and coronary 
artery disease risk showed a limited prediction in disease-free 
subjects (17). Similarly, evaluating asymptomatic cerebrovascular 
damage, no relationship was found between hematocrit and IMT 
(18). As to NAFLD, there is evidence that hematocrit levels are 
independently associated with fibrosis in NAFLD patients (19). 
Another blood cell component showing to play a role in coronary 
artery disease (20) is the mean volume of platelets, while their 
total count predicts fibrosis severity, but not steatosis grade in 
patients with liver-biopsy confirmed NAFLD (21, 22).
Apart data that shows an association between advanced and 
well-established forms of CV disease and blood components, little 
evidence exists about the link between hematological parameters 
and early stages or subclinical CV diseases, characterized by early 
atherosclerosis (23) in obesity-related NAFLD patients.
As previously stated, carotid IMT is increasingly regarded as a 
surrogate marker for assessing the initial process of atherosclerosis, 
its ability relying on predicting future clinical CV end-points (24). 
Focusing on ultrasonographic (US) evidence of IMT, we aimed 
at detecting any correlations between this vascular parameter and 
any component of blood count in a population of obese patients, 
with ultrasonography (US) feature of NAFLD. We also analyzed 
canonical and non-canonical cardio-metabolic risk factors, such 
as increased age, gender, smoking status, blood pressure, body fat 
distribution, both systemic and hepatic insulin resistance, lipid 
profile—including triglyceride/high-density lipoprotein (HDL) 
cholesterol ratio and the atherogenic index of plasma (AIP), 
markers of acute and chronic inflammation, C-reactive protein 
(CRP), fibrinogen, ferritin, and spleen volume (25).
MaTerials anD MeThODs
This cross-sectional study was performed enrolling 100 obese 
patients characterized by low prevalence of co-morbidities, 
without any history or sign of CV disease but with US findings 
of NAFLD. The research protocols were approved by the Ethics 
Committee of the Federico II University Medical School of Naples 
(protocol number: 231-05). All participants provided their writ-
ten informed consent to participate in this study.
exclusion criteria
Previous or recent CV diseases, such as coronary artery dis-
ease, cerebrovascular disease, or peripheral artery disease were 
excluded on the basis of history and appropriate testing. Any viral, 
autoimmune, metabolic liver disease (Wilson disease, hemochro-
matosis, or antitrypsin deficiency) was ruled out. Celiac disease 
was excluded on the grounds of the IgA anti-tissue transglutami-
nase antibodies absence. Alcohol abuse tested according to the 
DSM-IV diagnostic criteria, carrying out screening tests such as 
MAST (Michigan Alcohol Screening Test) and CAGE (Cut down, 
Annoyed, Guilty, and Eye opener), as well as random tests for 
blood alcohol concentration and the use of a surrogate marker, 
e.g., mean corpuscular volume (MCV). The therapy of patients 
was maintained according their schedules.
Metabolic Profile
Overweight and the class of obesity (I, II, III) was set by body 
mass index (BMI) cut-offs, i.e., 25–29.9, 30–34.9, 35–39.9, 
and >40  kg/m2, respectively. Abdominal obesity was assessed 
evaluating waist circumference (WC) measured at the midpoint 
between the lower border of the rib cage and the iliac crest. Hip 
circumference was measured around the widest part of the but-
tocks, with the tape parallel to the floor, and the waist-to-hip ratio 
(WHR) was calculated.
The canonical Adults Treatment Panel III was chosen to 
define the metabolic syndrome, considering at least three criteria: 
plasma glucose concentrations ≥100  mg/dL, WC >102/88  cm 
(male/female), serum HDL concentration <50 mg/dL for women 
and <40 mg/dL for men, blood pressure ≥130/85 mm Hg, and 
serum triglyceride concentration ≥150 mg/dL. Insulin resistance 
was studied by the HOmeostatic Metabolic Assessment (HOMA) 
method with the formula: fasting insulin (μU/mL)  ×  fasting 
glucose (mg/dL)/405 (26). A value of HOMA >2 was introduced 
as limit of the presence of insulin resistance (25). More than five 
determinations of HOMA in different situations were taken into 
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account. Triglyceride values of subjects who had fasted at least 
12/14  h before the blood draw were evaluated, averaging the 
results of at least two determinations, made on different days. 
Moreover, the triglyceride/HDL cholesterol ratio was evaluated, 
considering abnormal values ≥1.65 (men) and ≥1.32 (women) 
(27, 28). Low-density lipoprotein (LDL) was calculated by the 
following formula: LDL = total cholesterol − HDL − (triglycer-
ides/5). A new index evaluating hepatic insulin resistance, gener-
ated through stepwise linear regression, i.e., 2.2607 + 0.427 × log 
HOMA was computed (29). The AIP was calculated according to 
the following formula: AIP = log triglycerides/HDL (30).
Ultrasonography Features
The spleen diameter, assessed on longitudinal scan, was chosen 
to evaluate the spleen volume and was carried out by the postero-
lateral approach. The classification of hepatic steatosis/NAFLD 
was based on the following scale of increased echogenity: grade 
0 = absent, 1 =  light, 2 = moderate, 3 = severe, unraveling the 
difference between the densities of the liver and the right kidney 
obtained on the same longitudinal sonographic plane. The levels 
of brightness of the liver and right kidney were calculated three 
times directly from the frozen images. Subcutaneous adipose 
tissue (SAT) and visceral adipose tissue (VAT) were assessed by 
transverse scanning. SAT was defined as the thickness between 
the skin-fat interface and the linea alba, avoiding compression. 
VAT was defined as the distance between the anterior wall of 
the aorta and the internal face of the recto-abdominal muscle 
perpendicular to the aorta, measured 1 cm above the umbilicus. 
When the aortic walls were obscured by bowel gas, a Doppler 
scan was used to detect them (25). The common carotid artery, 
the carotid bulb, and the near and far wall segments of the inter-
nal carotid artery were scanned bilaterally. Images were obtained 
in longitudinal sections with a single lateral angle of insonation, 
optimizing the image for the far wall. IMT was defined as the dis-
tance between the ultrasound interfaces of the lumen-intima and 
media-adventitia. Six manual measurements were performed, 
with automatic border detection, at equal distances along 1 cm 
on the far wall of the common carotid, according to the consen-
sus statement from the American Society of Echocardiography 
Carotid Intima-Media Thickness Task Force, endorsed by the 
Society for Vascular Medicine (31).
Blood Pressure Measurements
Systolic/diastolic blood pressure values were obtained averaging 
three consecutive measurements taken during usual practice 
hours, after subjects had rested for 5 min in the sitting position.
laboratory Data
Blood samples were collected from all participants in the early 
morning after an overnight fast. An automated hematologic ana-
lyzer (Coulter LH750) was used to measure total and differential 
blood parameters/counts. Testing for serum triglycerides, HDL, 
fasting insulin, alanine transferase (ALT), gamma-glutamyl trans-
ferase, alkaline phosphate, cholinesterase, fasting glucose, fasting 
insulin, fibrinogen, and ferritin were performed at enrollment by 
in-house standard procedures. Hs-CRP values, determined by 
the ELISA test, with reference values between 0.3 and 8.6 mg/L 
in healthy men and between 0.2 and 9.1 mg/L in healthy women 
(BioCheck, Inc., CA, USA) were determined in collected and 
aliquoted samples and frozen at −20°C.
Smoking status was categorized into five classes, i.e., class 1 as 
non-smokers, class 2 as past smokers, class 3 as social/weekend 
smokers, class 4 as light/moderate smokers, and finally class 5 as 
active smokers.
statistics
The Kolmogorov–Smirnov test was evaluated to detect whether 
the variables were normally distributed and accordingly were 
reported as mean plus SD. Variables not normally distributed were 
expressed as median (25–75 IQR). The difference in medians was 
assessed by the Mann–Whitney test for independent samples. 
Chi-square evaluated frequencies. The two-way cross-tabulation 
was performed to assess the relation between the severity of 
obesity and gender on the one hand, and hepatic steatosis grade 
at ultrasonography on the other. As exploratory step, the degree 
of the association between single parameters was studied using 
Spearman’s coefficient of rank correlation (ρ) for non-uniform 
intervals. To assess the independent effect of a quantitative 
variable (predictor or explanatory) on eventual prediction of 
another one, the linear regression analysis (least squares) was 
used evaluating the coefficient and the t (t-value). As multivariate 
analysis, the multiple regression was adopted (Backward Stepwise 
Selection), first entering all independent variables if P = 0.05 into 
the model (at univariate analysis), and then removing if P = 0.1 
the non-significant variables sequentially, with a maximum 
number of 10 steps. IMT was chosen as dependent variable. To 
appreciate which variables contribute to any extent to the regres-
sion equation, the magnitude of standardized coefficient beta 
(β) was calculated. To assess multicollinearity, variance inflation 
factor and tolerance were set at >10 and <0.1, respectively. The 
effect size was calculated evaluating the R2 (<0.25: small, from 
0.25 to 0.64: medium, ≥0.65: large). The maximum number of 
variables put in the multiple regression analysis never exceeded 
the ratio of one variable to 10 patients. When analyzing a dataset 
in which there was one independent variable that determined an 
outcome, measured with a dichotomous variable—i.e., no smok-
ing status—the logistic regression was performed (OR and 95% 
CI or coefficient plus SE).
The concordance correlation coefficient (ρc), which measures 
precision and accuracy, was adopted to evaluate the degree of 
pair observations at ultrasonography. The statistical analysis was 
performed operating on Systat 13 (Richmond, CA, USA) and 
MedCalc Version 15.2.1 ® (Frank Schoonjans) software packages.
resUlTs
Characteristics of the whole population are shown in Table  1. 
The most part of patients (89%) showed obesity of second and 
third class, without any difference for gender (cross-tabulation 
P =  0.4). Specifically, referring to class I/II/II/of obesity there 
were 7/26/35 females, respectively, while 4/18/20 were males 
belonging to the aforementioned classes. Concerning the meta-
bolic syndrome presence, 31 females out of 68 and 26 males out 
of 32 fulfilled the criteria, chi-square 11.29, P = 0.0007. Hepatic 
TaBle 3 | Predictions at univariate analysis.
coefficient t P
IMT Age 0.0012 6.77 <0.0001
IMT Hematocrit 0.0026 3.45 0.001
IMT Platelets count −0.00000017 −3.09 0.0025
IMT Mean corpuscular volume 0.0011 3.28 0.0014
HOMA Hematocrit 0.0045 2.7 0.007
IMT, intima-media thickness; HOMA, HOmeostatic Metabolic Assessment.
TaBle 2 | The most relevant associations.
IMT Hematocrit ρ = 0.353 P = 0.003
IMT Hemoglobin ρ = 0.28 P = 0.004
IMT Platelets count ρ = 0.30 P = 0.0
Hemoglobin Mean corpuscular volume ρ = 0.4 P < 0.001
Hematocrit Hepatic steatosis severity ρ = 0.23 P = 0.021
Hepatic insulin resistance Hepatic steatosis severity ρ = 0.27 P = 0.007
Triglyceride/HDL ratio WC ρ = 0.325 P = 0.007
γ-GT HOMA ρ = 0.50 P = 0.0001
γ-GT Ferritin ρ = 0.48 P = 0.001
HOMA Hematocrit ρ = 0.29 P = 0.029
IMT, intima-media thickness; HOMA, HOmeostatic Metabolic Assessment; γ-GT, 
gamma-glutamyl transglutaminase; WC, waist circumference; HDL, high-density 
lipoprotein cholesterol; ALT, alanine transferase.
Metabolic syndrome occurred much more frequently in those patients who presented 
an elevation of both ALT and γ-GT serum levels. (Spearman ρ 0.59 with P = 0.001 and 
0.41 with P = 0.001, respectively).
TaBle 1 | Characteristics of obese patients with non-alcoholic fatty liver disease (n = 100), including metabolic parameters.
Gender M/F 32/68 Age 43.5 (32–52)
BMI 40.7 (37.1–45.1) BM I > 45 (n) 26
WC females (cm) 118.8 ± 16.1 WC males (cm) 132.8 ± 110.6
WHR males 1.02 ± 0.05 WHR females 0.90 ± 0.06
SAT (cm) 2.8 ± 0.06 VAT (cm) 7.3 ± 0.06 2.1
Ferritin females (ng/mL) 38.5 (19.5–70.5) Ferritin males (ng/mL) 169.7 (140–197)
Fibrinogen (g/L) 323 (285.5–356) CRP (mg/mL) 0.46 (0.24–0.89)
γ-GT (U/L) 22.5 (14.5–36) ALT (U/L) 23 (18–33)
Triglycerides (mg/dL) 104.5 (76.5–160.5) LDL (mg/dL) 169.7 (140.3–1.97)
HDL females (mg/dL) 50.8 ± 11.05 HDL males (mg/mL) 43.7 ± 9.06
Triglyceride/HDL ratio (females) 1.93 (1.38–2.81) Triglyceride/HDL ratio (males) 3.26 (1.61–4.82)
AIP (females) 0.29 ± 0.23 AIP (males) 0.50 ± 0.36
Hepatic IR 2.4 (2.3–2.5) HOMA 2.4 (1.32–3.72)
SBP (mm Hg) 130 (120–130) DBP (mm Hg) 80 (75–100)
IMT > 0.9 mm (yes/no) 35/65 IMT (mm) 0.08 (0.07–0.10)
Hematocrit (females) 39.8 ± 2.99 Hematocrit (males) 44.5 (42.4–46)
White blood cells (mm3) 7,750 (6,700–8,850) Neutrophil lymphocyte ratio 2.06 (1.62–2.31)
Hemoglobin (females) (g/dL) 13.5 ± 1.14 Hemoglobin (males) (g/dL) 15.1 (14.5–15.6)
MCV 86.7 (82.7–90.1) Platelet count (109/L) 254 ± 54
Spleen longitudinal diameter (mm) 11.23 ± 0.14 Spleen longitudinal diameter > 12 mm (n) 15
Values were expressed as m ± SD or median (25–75 IQR).
n, number of patients; WC, waist circumference; BMI, body mass index; WHR, waist-to-hip ratio; SAT, subcutaneous adipose tissue; VAT, visceral adipose tissue; HDL, high-density 
lipoprotein cholesterol; CRP, C-reactive protein; ALT, aminotransferase; γ-GT, gamma-glutamyl transglutaminase; LDL, low-density lipoprotein cholesterol; HOMA, HOmeostatic 
Metabolic Assessment; SBP, systolic blood pressure; DBP, diastolic blood pressure; IMT, intima-media thickness; AIP, atherogenic index of plasma; MCV, mean corpuscular volume.
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steatosis was related to the degree of obesity (cross-tabulation 
P =  0.014). Hypertension occurred only in 4 obese patients, 
while type 2 diabetes mellitus in 16, confirming the low preva-
lence of co-morbidities. Nearly one-third of patients presented 
an increase in carotid IMT. Interestingly, only 45 subjects were 
labeled as active smokers versus 35 self-declared no-smokers or 
past smokers, while the remainders were light or weekend smok-
ers. Insulin resistance, evaluated as HOMA >2 and present in 
56 obese patients, was significantly higher in those diagnosed at 
US with moderate compared to mild grade of hepatic steatosis 
(median 2.65 versus 1.42, P =  0.006 and Mann–Whitney U). 
Hepatic insulin resistance in males was lower than systemic 
insulin resistance, expressed as HOMA, i.e., median 2.48 versus 
3.49, P = 0.003; in females, there was no difference, i.e., median 
2.39 versus 2.02, P =  0.45, Mann–Whitney U. The hematocrit 
mean value was in both gender generally at the upper limit of 
normality.
associations
The most relevant correlations are shown in Table 2.
Furthermore, IMT was not related to white blood cells 
(ρ = 0.09, P = 0.35) or neutrophil count (ρ = 0.12, P = 0.24). There 
was a trend of significance concerning the relationship between 
BMI and platelets count (ρ = 0.19, P = 0.056) and between hepatic 
steatosis grade at US and IMT (ρ = 0.18, P = 0.07).
Univariate analysis
The most relevant predictions at linear regression are shown in 
Table 3.
Intima-media thickness was not predicted by white blood cells 
count, neutrophils, and neutrophil/lymphocyte ratio, P =  0.13, 
0.19, and 0.94, respectively. Noticeably, hematocrit was not 
predicted by age, P = 0.17. As collateral finding, MCV was not 
predicted by WC, P = 0.8.
As expected, IMT was predicted by smoking status, coeffi-
cient 0.0067, t = 3.51, P = 0.001. In details, non-smoking status 
was predicted by hematocrit, OR 0.77, 95% CI =  0.67–0.89, 
P = 0.0002.
Multivariate analysis
First of all, studying classical risk factors for atherosclerosis, IMT 
was predicted only by LDL among the metabolic parameters, i.e., 
hepatic insulin resistance, HOMA, LDL, HDL, AIP, triglyceride/
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HDL, with coefficient 0.0001, β =  0.25, t =  2.58, P =  0.011, 
R2 = 0.06.
Adding to the model predicting IMT, (i) blood count factors 
(hematocrit, MCV, and platelets), (ii) age, and (iii) smoking habit, 
resulted to be predicted by age and hematocrit, coefficient 0.001, 
β = 0.55, t = 6.57, P < 0.001, and coefficient 0.0020, β = 0.30, 
t = 3.199, P = 0.0019, R2 = 0.38, respectively. It is worth under-
lining that hemoglobin was excluded from the analysis due to 
collinearity with MCV.
Successively, evaluating the role of anthropometric features, 
among BMI, WC, WHR, SAT, and VAT, IMT was predicted by 
VAT alone, with coefficient −0.0085, β = 0.49, t = 5.5, P < 0.0001, 
R2 = 0.24.
Furthermore, age and hematocrit, adjusted for VAT, main-
tained their predictive value, although there was a reduction of 
more than 20% of the coefficient, lending credence to the fact 
that visceral adiposity is a real confounding factor. The results 
for age were coefficient 0.001, β = 0.47, t = 5.3, P < 0.0001; for 
hematocrit: coefficient 0.001, β = 0.24, t = 2.48, P = 0.014, for 
VAT: coefficient 0.002, β = 0.225, t = 2.2, P = 0.025, R2 = 0.41. 
Finally, when these three variables predicting IMT, i.e., age, 
hematocrit, and VAT were adjusted for gender, this variable was 
excluded from the model, evidencing its lack of influence.
reliability
To substantiate the clinical significance of US features, the inter-
intra-observational reproducibility of the sonographic estima-
tions was high, with a ρc of 0.93 and 0.89, respectively.
DiscUssiOn
In our studied population (obese patients of second and third 
grade, with low prevalence of co-morbidities but suffering from 
NAFLD), both age and hematocrit values predicted IMT, also 
after adjusting for other evidenced predictors of IMT, i.e., amount 
of the visceral adiposity, expressed as VAT and evaluated by US 
and smoking habit. Noteworthy, the latter was also predicted by 
hematocrit in line with a previous study that found an increase 
in hematocrit values among smokers and in heavy smokers, 
these changes likely predisposing to greater risk of developing 
atherosclerotic plaques and coronary heart disease (32).
Concerning other blood count components, white blood cells 
and neutrophil count did not show any relation to IMT in our 
population. Considering both these blood components as inflam-
matory markers, interestingly our data on CRP are in agreement 
with the latter finding, in the sense that this acute phase protein 
was not associated with IMT in our population, partially in 
accordance with other results showing that CRP and carotid IMT 
levels appear to be directly related in women, but not in men in a 
population of 2,640 subjects, gender equally represented, differ-
ently from our study (33).
Analyzing the possible mechanisms underlying the associa-
tion between hematocrit levels and early atherosclerosis, blood 
viscosity is central to explaining this phenomenon. Unfortunately, 
recent literature offers divergent data. In fact, Carallo et  al. 
demonstrate that blood viscosity seems independent of classical 
coronary heart disease risk factors and is unrelated to hematocrit 
and plasma viscosity, suggesting a possible direct effect of aging 
on red blood cells (34). By contrast, the passage time, another 
index of blood rheology, correlated better with hematocrit 
(r = 0.422) than white blood cell count (r = 0.295) and platelet 
count (r = 0.204) (35).
Confronting the aforementioned data, we hypothesize that 
red blood cells increase the adhesiveness of platelets by the 
erythrocyte-derived ADP available for platelet activation and 
causes the dispersion of platelets toward the sub-endothelial 
surface due to blood flow (36, 37). Experimental studies have sug-
gested that red blood cells promote thrombin generation and that 
the thrombin concentration is proportionate to hematocrit levels 
(38, 39). As a result, hematocrit could promote thrombosis and 
atherosclerosis, and consequently CV disease. The finding that in 
humans blood viscosity, evaluated as hematocrit, is involved in 
the endothelial response to an increase in shear stress confirms 
the role of hematocrit in hypertension and consequently in the 
atherosclerotic process (40).
The relationship between obesity-related NAFLD and athero-
sclerosis via thrombotic mechanisms should not be overlooked. 
In fact, in a rat model of NAFLD, induced by feeding a fat-rich diet 
for 24 weeks, the imbalance of plasma PGI2 and thromboxane A2 
(TXA2) levels played a role in the pathogenesis of NAFLD (41). 
TXA2, a marker of platelet activation, evaluated as serum levels 
thromboxane B2, is higher in obese subjects than in lean ones, 
and this might be a clue to their increased CV risk (42).
To draw further conclusions from our results, it is worth 
mentioning that hematocrit was positively associated with insulin 
resistance—evaluated as HOMA—an association considered an 
epiphenomenon of visceral adiposity (18). The latter finding con-
firms that an interplay between alterations of adipose tissue dis-
tribution/function and hematocrit could be involved determining 
broad effects on in the induction/maintenance of atherosclerosis. 
As partially supporting evidence, taking into account that insulin 
resistance is a major underlying mechanism responsible for the 
“metabolic syndrome,” which is also known as insulin resistance 
syndrome, authors found that beyond elevated levels of hemo-
globin and red blood cells counts hematocrit was significantly 
associated with clustered components of metabolic syndrome in 
women (43). It is necessary to highlight that differences in defini-
tions of CV disease risk, as well as ethnic and racial differences 
may account for the absence of consistency across studies.
We did not assess the prevalence of abnormal blood data in 
our obese patients, extensively reported elsewhere (44), nor were 
able to confirm previous data from others concerning the link 
between hepatic steatosis severity and white blood cells count. 
Indeed, recent research clearly showed that white blood cells 
count was a significant factor associated with incident NAFLD 
in Han Chinese without NAFLD at base line, with a HR of 1.152 
in the highest quartile, obtained by Cox proportional hazards 
regression analysis (45).
The role of NAFLD in predicting IMT was not definitely 
evident in this study, but we emphasize that the NAFLD severity 
was not assessed by histology, due to the lack of consent to inva-
siveness by our obese patients. Supportively, we stress that IMT 
was predicted by the visceral adiposity, a clear sign of NAFLD 
presence, directly or indirectly representing a CV risk factor (46).
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Accordingly, it should be stressed that visceral adiposity was a 
real confounding factor in predicting IMT, consequently playing 
a noticeable role in determining/worsening atherosclerosis. In 
multiple regression, the lack of retaining of smoking as predictor 
of IMT is likely due the reduced number of active smokers in our 
population and multicollinearity with age, according to recent 
investigation (47).
The apparently surprising negative correlation between IMT 
and platelets count is likely due to the treatment with anti-platelet 
drugs and to vitamin B12 and/or folate deficiency, often present 
in the obese, according to de Ilvar et al. (48).
Coming back to our core finding, when comparing our results 
with relevant findings from other reports of literature by principal 
search sources during the last decade, interesting data, although 
not univocal, was found about the relation between hematocrit 
levels and CV disease risk factors. In fact, this association has been 
reported inconsistently. Recent findings suggest that both elevated 
and decreased hematocrit levels are associated with an increased 
risk of established CV disease, even though the more significant 
risk was found in the highest quartile of patients with ischemic 
stroke and coronary artery disease (49). On the other hand, the 
study of Arbel et al., found that, in patients with angiographically 
normal coronary arteries and slow coronary flow, hematocrit 
levels are associated with slower coronary blood flow (SCF). The 
phenomenon of SCF in the presence of normal coronary arteries 
may indicate endothelial dysfunction, which is characteristic of 
an early stage in the development of atherosclerosis. Despite this 
association, such patients do not have increased carotid IMT 
values (50). In line with our results stands a study by Tabara et al. 
including 1,978 participants from two independent cohorts, which 
showed that hematocrit was positively associated with insulin 
resistance and insulin sensitivity. However, this association was 
lost after further adjustment for visceral fat area and plasma ALT, 
concluding that this association was epiphenomenon of visceral 
adiposity and hepatic fat excess (18).
limitations
First, we acknowledge that the type of study did not allow us to 
draw conclusions on the direction of the associations.
Second, ours was a single-center study, and large-scale 
prospective studies are needed to confirm this association and 
establish whether this new information is sufficient to modify 
existing clinical practice.
Possible drawbacks were not having evaluated the adipose 
districts by the more precise magnetic resonance imaging and 
NAFLD by histology. Anyway, US-detecting NAFLD is a reliable 
technique in epidemiological studies (51).
Finally, having selected a population with low rate of co-
morbidities, which presented relatively few CV risk factors, has 
its limitations.
cOnclUsiOn anD FUTUre DirecTiOns
The combination of hematocrit measurements with one of the 
“canonical risk factors,” e.g., the patients’ age, can improve our 
ability to detect an early atherosclerosis in the obese. Future 
observational studies in this setting, comparing patients with low 
and high rate of co-morbidities, will play an important role in the 
decision-making process providing invaluable information on 
the reliability of hematocrit determinations at the light that these 
are widely available, easy to carry out and interpret. Specifically, 
as implications for current practice, hematocrit values can alert 
physician to the need of making a quick diagnosis of incident 
cardio-metabolic cases when facing such patients with low rate 
of co-morbidities but NAFLD. Obese patients affected by vari-
ous co-morbidities are likely to have more severe or premature 
atherosclerosis due to combined mechanisms and it would be 
extremely interesting whether hematocrits still remain a predic-
tor of carotid IMT. Indeed, such patients requiring more frequent 
physician visits have greater opportunity to undergo screening or 
to have early symptoms of CV disease investigated.
As corollary of our finding, hematocrit determinations could 
have a further significant impact on clinical decision, mainly 
on cutting back the spending of the health care system and 
consequently costs in a real-world environment. Finally, this 
study merits further research in the sense that a better and more 
nuanced understanding of the molecular basis underlying the 
association between hematocrit and carotid IMT and its patho-
genic pathways may lead to new strategies to improve CV health 
as well as overall health and increase longevity.
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